• Follow Us On : 

Jacobson Pharma Submits Form A1 to Spin-off Its Branded Healthcare Business

Redaksi | Rabu,23 September 2020 - 11:51:47 WIB
Dibaca: 593 kali 
Jacobson Pharma Submits Form A1 to Spin-off Its Branded Healthcare Business

CHINA - Media OutReach - 23 September 2020 - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or "the Group"; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare products in Hong Kong, has today announced that its subsidiary, JBM (Healthcare) Limited ("JBM"), has submitted the application (Form A1) to apply for the listing of and permission to deal in its shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX). The separate listing of JBM constitutes a proposed spin-off of JBM by the Group under the Listing Rules.

JBM is a Hong Kong-based branded healthcare company with product footprint covering Greater China, Southeast Asia and certain other countries. It is principally engaged in the manufacturing and trading of branded healthcare products, comprising consumer healthcare products and proprietary Chinese medicines. Currently, Jacobson Pharma indirectly holds 85.04% of JBM Shares. Upon completion of the proposed spin-off, Jacobson Pharma intends to hold not less than 50% of the shares of JBM and that the Group will still consolidate its accounts.

Jacobson Pharma considers the proposed spin-off will be in the interest of the Group and its Shareholders as a whole. The Group also believes that the proposed spin-off will better position itself and JBM for further growth in their respective businesses and deliver clear benefits to both due to the following reasons:

Enhance strategic and management focus
The nature of products offered under the Group's generic drug business and JBM's branded healthcare business is distinct and different and as such the two businesses require different business plans and strategic and management focus. The proposed spin-off will enable JBM to focus on sustaining its competence and competitiveness in brand and marketing management, as well as creating values through product portfolio management, while Jacobson Pharma will focus on strengthening its technical competence and in-licensing capabilities in pursuing first-to-file or first-to-market generic drugs.

Nimble branded healthcare company
Market demands and consumer preferences for branded healthcare products evolve rapidly. The proposed spin-off will allow JBM to become better focused and nimble, with the ability to quickly focus on and deliver consumer-preferred branded healthcare products.

Unlock value of branded healthcare business and enhance overall value of the Group
The proposed spin-off will allow investors to separately value the branded healthcare business of JBM and the retained business of the Group based on their distinct investment identities. The proposed spin-off will also enable Jacobson Pharma to benefit from the potential strategic value of JBM as its majority shareholder after the proposed spin-off, and may have the effect of enhancing the value of the Group as a whole.

Direct access to capital markets for JBM
The proposed spin-off will provide JBM with its own listing platform, and as a result, create an independent equity structure that will allow JBM to have direct and independent access to the capital markets for debt and equity fund raising to support its business growth, identify strategic partners and facilitate its ability to capitalize on unique growth opportunities, as well as pursue potential merger and acquisitions with its own resources.

Enhance risk management
In general, generic drugs and branded healthcare products have different risk management profiles and require different management skillsets and risk management systems. The proposed spin-off will allow the management of the two companies to better utilize risk management tools and internal control procedures to safeguard their respective businesses and assets.

Geographical segregation
The proposed spin-off will enable JBM to direct greater focus, effort and resources towards capturing demand from habitual and brand-loyal customers, especially from China and other Asian countries, in particular, through well-strategized brand promotions via both online and offline advertising and marketing campaigns. Synergies in terms of sharing of marketing campaigns, research findings and regulatory resources are also expected to be realized among various products and markets, while the branded healthcare business seeks to expand in its size, market share and geographical coverage.

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, said, "This spin-off initiative will act as a catalyst for resetting both our capabilities and cost base, as well as delivering value-creation opportunities to both businesses. It is also a significant step forward in terms of shaping Jacobson into a company comprising two distinct enterprises: one that is intently focused on its core generic drugs and specialty medicines business, while the other is principally focused on consumer health and wellness product offerings. We are confident that the proposed spin-off will create growth opportunities and value for the shareholders of Jacobson Pharma and JBM in the long term."

Akses Wahanariau.com Via Mobile m.Wahanariau.com
Untuk Berbagi Berita / Informasi / Peristiwa
Silahkan SMS ke nomor HP : 085271472010
atau email ke alamat : [email protected]
Harap camtumkan detail data diri Anda
Pengutipan Berita dan Foto, Cantumkan Wahanariau.com Sebagai Sumber Tanpa Penyingkatan
Senin,25 Januari 2021

JBM Limited to Be Spun Off from Jacobson Pharma Corporation Limited

Announces Details of Proposed Listing on Main Board of SEHK Highlights The fourth largest brand o

Selasa,26 November 2019

Jacobson Pharma Announces FY2020 Interim Results

Profit Attributable to Shareholders Lifted by 30.5% Portfolio and Market Expansion to Harness Gro

Rabu,05 Februari 2020

Jacobson Pharma Launches First Influenza RSV Home Diagnostic Kit in Hong Kong and Macau

CHINA - Media OutReach - 5 February 2020 - Jacobson Pharma Corporation Limited ("Jacobson Pharm

Kamis,22 November 2018

Jacobson Pharma Announces FY2019 Interim Results

Profit from Operations Leapt by 40.7% to HK$158.6 Million Declares Interim Dividend of HK1

Kamis,31 Oktober 2019

Jacobson Pharma Forms Joint Venture with Kin Fung Weisen-U

Expands Branded Product Portfolio and Develops New Markets for Gastrointestinal and Respiratory Prod

Jumat,15 Januari 2021

Jacobson Pharmas Proposed Spin-off and Separate Listing of JBM Limited on The Main Board of The Stock Exchange of Hong Kong Limited

Declaration of Conditional Special Interim Dividend HONG KONG SAR - 15 January 2021 - Jacobson Phar

Sabtu,01 Oktober 2022

Adryan Nathanael Rilis Single Pop Elektro Terbaru Harapku

BANDUNG - Dalam melahirkan karya lagu, Adryan Nathanael konsisten mengusung aliran musik pop elektro

Sabtu,01 Oktober 2022

Baksos HUT Kadin, Masyarakat Desa Pulau Palas Bahu-membahu Bedah Rumah Zulkifli

TEMBILAHAN - Masyarakat Desa Pulau Palas, Kecamatan Tembilahan Hulu, Kabupaten Indragiri Hilir (Inhi

Jumat,30 September 2022

Telah Hadir Kapal MV Oceanna Group Bawa Rombongan Umroh

DUMAI - Masyarakat Kota Dumai saat ini bisa berangkat melaksanakan ibadah umroh dengan menggunakan j